IP Library Granted Patent US 10,155,787
Granted Patent B2
US 10,155,787 · App. 14/947,680 · Granted Dec 18, 2018

Preparation and uses of obeticholic acid

Inventors: André Steiner (Raubling, DE); Heidi Waenerlund Poulsen (Køge, DK); Emilie Jolibois (Cambridge, GB); Melissa Rewolinski (San Diego, CA); Ralf Gross (Raubling, DE); Emma Sharp (Cambridge, GB); Fiona Dubas-Fisher (Cambridge, GB); Alex Eberlin (Cambridge, GB)
Assignee: Intercept Pharmaceuticals, Inc.
C07J9/005A61K9/2054A61K31/575C07J51/00C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,155,787
App. No.
14/947,680
Granted
Dec 18, 2018
Kind
B2
Abstract

The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.

Claims (31)

1. A process of preparing non-crystalline obeticholic acid comprising less than 1% of chenodeoxycholic acid comprising the step of

converting crystalline obeticholic acid to non-crystalline obeticholic acid, wherein the crystalline obeticholic acid is prepared by a process comprising,

reacting E- or E/Z-3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oic acid with Pd/C and hydrogen gas to form 3α-hydroxy-6α-ethyl-7-keto-5β-cholan-24-oic acid,

reacting 3α-hydroxy-6α-ethyl-7-keto-5β-cholan-24-oic acid with NaBH 4 to form crude obeticholic acid, and

at least one step of crystallizing crude obeticholic acid using at least one organic solvent,

wherein converting crystalline obeticholic acid to non-crystalline obeticholic acid comprises the step of dissolving crystalline obeticholic acid in aqueous NaOH solution and adding HCl.

2. The process of claim 1 , further comprising the step of

reacting E- or E/Z-3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oic acid methyl ester with NaOH to form E- or E/Z-3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oic acid.

3. The process of claim 2 , further comprising the step of

reacting 3α,7-ditrimethylsilyloxy-5β-chol-6-en-24-oic acid methyl ester with CH 3 CHO to form E- or E/Z-3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oic acid methyl ester.

4. The process of claim 3 , further comprising the step of:

reacting 3α-hydroxy-7-keto-5β-cholan-24-oic acid methyl ester with Li[N(CH(CH 3 ) 2 ) 2 ] and Si(CH 3 ) 3 Cl to form 3α,7-ditrimethylsilyloxy-5β-chol-6-en-24-oic acid methyl ester.

5. The process of claim 4 , further comprising the step of:

reacting 3α-hydroxy-7-keto-5β-cholan-24-oic acid with CH 3 OH and H 2 SO 4 to form 3α-hydroxy-7-keto-5β-cholan-24-oic acid methyl ester.

6. The process of claim 5 , wherein reacting 3α-hydroxy-6α-ethyl-7-keto-5β-cholan-24-oic acid with NaBH 4 to form crude obeticholic acid is carried out at a temperature at about 85° C. to about 110° C. in a basic aqueous solution.

7. The process of claim 5 , wherein reacting E- or E/Z-3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oic acid with Pd/C and hydrogen gas to form 3α-hydroxy-6α-ethyl-7-keto-5β-cholan-24-oic acid is carried out at a temperature at about 90° C. to about 110° C.

8. The process of claim 5 , wherein reacting E- or E/Z-3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oic acid methyl ester with NaOH to form E- or E/Z-3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oic acid is carried out at a temperature at about 20° C. to about 60° C.

9. The process of claim 5 , wherein reacting 3α,7-ditrimethylsilyloxy-5β-chol-6-en-24-oic acid methyl ester with CH 3 CHO to form E- or E/Z-3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oic acid methyl ester is carried out in a polar aprotic solvent at a temperature at about −50° C. to about −70° C. in the presence of BF 3 .

10. The process of claim 5 , wherein reacting 3α-hydroxy-7-keto-5β-cholan-24-oic acid methyl ester with Li[N(CH(CH 3 ) 2 ) 2 ] and Si(CH 3 ) 3 Cl to form 3α,7-ditrimethylsilyloxy-5β-chol-6-en-24-oic acid methyl ester is carried out in a polar aprotic solvent at a temperature at about −10° C. to about −30° C.

11. The process of claim 5 , wherein reacting 3α-hydroxy-7-keto-5β-cholan-24-oic acid with CH 3 OH and H 2 SO 4 to form 3α-hydroxy-7-keto-5β-cholan-24-oic acid methyl ester is heated for about 3 hours and the pH of the reaction mixture is adjusted with an aqueous basic solution.

12. A process of claim 1 , wherein preparing crystalline obeticholic acid comprises at least one step of crystallizing crude obeticholic acid using at least one organic solvent selected from the group consisting of acetonitrile, heptane, nitromethane, and n-butyl acetate.

13. The process of claim 12 , wherein the at least one organic solvent is n-butyl acetate.

14. The process of claim 12 , wherein the crystalline obeticholic acid is characterized by a differential scanning calorimetry thermogram having an endothermic peak at 98±2° C.

15. A process of preparing non-crystalline obeticholic acid, comprising the steps of

reacting 3α-hydroxy-7-keto-5β-cholan-24-oic acid with CH 3 OH and H 2 SO 4 to form 3α-hydroxy-7-keto-5β-cholan-24-oic acid methyl ester in which the reaction is heated for about 3 hours and the pH of the reaction mixture is adjusted with an aqueous basic solution;

reacting 3α-hydroxy-7-keto-5β-cholan-24-oic acid methyl ester with Li[N(CH(CH 3 ) 2 ) 2 ] and Si(CH 3 ) 3 Cl to form 3α,7-ditrimethylsilyloxy-5β-chol-6-en-24-oic acid methyl ester in which the carried out in a polar aprotic solvent at a temperature at about −10° C. to about −30° C.;

reacting 3α,7-ditrimethylsilyloxy-5β-chol-6-en-24-oic acid methyl ester with CH 3 CHO to form E- or E/Z-3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oic acid methyl ester is which the carried out in a polar aprotic solvent at a temperature at about −50° C. to about −70° C. in the presence of BF 3 ;

reacting E- or E/Z-3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oic acid methyl ester with NaOH to form E- or E/Z-3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oic acid in which the reaction is carried out at a temperature at about 20° C. to about 60° C.;

reacting E- or E/Z-3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oic acid with Pd/C and hydrogen gas to form 3α-hydroxy-6α-ethyl-7-keto-5β-cholan-24-oic acid is which the reaction is carried out at a temperature at about 90° C. to about 110° C.;

reacting 3α-hydroxy-6α-ethyl-7-keto-5β-cholan-24-oic acid with NaBH 4 to form crude obeticholic acid is carried out at a temperature at about 85° C. to about 110° C. in a basic aqueous solution; and

converting crystalline obeticholic acid to non-crystalline obeticholic acid by dissolving crystalline obeticholic acid in aqueous NaOH solution and adding HCl, wherein the crystalline obeticholic acid is prepared by a process comprising at least one step of crystallizing crude obeticholic acid using at least one organic solvent.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2026
From: INTERCEPT PHARMACEUTICALS, INC.
To: ALFASIGMA S.P.A
Reel/Frame 075044/0679 →
RELEASE OF SECURITY INTEREST Recorded Jan 4, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 066662/0210 →
CHANGE OF ADDRESS Recorded Aug 22, 2022
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 061297/0804 →
SECURITY INTEREST Recorded Aug 18, 2021
From: INTERCEPT PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 057650/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2017
From: SHARP, EMMA; JOLIBOIS, EMILIE; DUBAS-FISHER, FIONA; EBERLIN, ALEX
To: SIGMA-ALDRICH COMPANY LTD.
Reel/Frame 041480/0334 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2017
From: PHARMAZELL GMBH
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 041480/0409 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2017
From: SIGMA-ALDRICH COMPANY LTD.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 041480/0443 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2017
From: GROSS, RALF; STEINER, ANDRE; WAENERLUND POULSEN, HEIDI
To: PHARMAZELL GMBH
Reel/Frame 041480/0379 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2017
From: REWOLINSKI, MELISSA
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 041480/0248 →
Continuity (3)
Division 13919734 · Jun 17, 2013
Provisional Application 61661531 · Jun 19, 2012
Related Publication 20160215014A1 · Jul 28, 2016